dihexa scopolamine 2019 45802058084 Scopolamine 1 mg / 3

Jackson et al., 2018

Cagrilintide Regulatory Status As of June 2026, cagrilintide is investigational and is not FDA-approved in any form

If these peptides are added to the bulk compounding list, compounding pharmacies would be permitted to use them to prepare compound products

It works by supporting tissue repair, which takes time

No lethal dose identified at doses up to 20 mg/kg in animal studies No organ toxicity observed across multiple organ systems Negative mutagenicity testing across standard assays No teratogenic effects in pregnancy studies Limited long-term human data beyond 6 weeks Theoretical Considerations The primary theoretical concern relates to BPC-157s angiogenic properties